Regulation of pyruvate kinase type M2 by A-raf: A possible glycolytic stop or go mechanism

Anticancer Research

Volumn 27, Issue 6 B, 2007, Pages 3963-3971

  Mazurek, Sybille ^a,b   Drexler, Hannes C A ^c,e   Troppmair, Jakob ^d   Eigenbrodt, Erich ^a   Rapp, Ulf R ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b ScheBo Biotech AG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

Author keywords

A Raf; Glutaminolysis; M2 PK; Pyruvate kinase; Serinolysis; Tumor metabolome

Indexed keywords

A RAF KINASE; GLUTAMINE; PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; SERINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LINE; CONTROLLED STUDY; ENZYME KINETICS; ENZYME MECHANISM; ENZYME REGULATION; GLYCOLYSIS; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; FIBROBLASTS; GLUTAMINE; GLYCOLYSIS; HT29 CELLS; HUMANS; IMMUNOPRECIPITATION; MICE; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS A-RAF; PYRUVATE KINASE; SERINE;

EID: 37549020279     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Eigenbrodt E, Fister P and Reinacher M: New perspectives on carbohydrate metabolism in tumor cells. In: Regulation of Carbohydrate Metabolism. Beitner R (ed.). Boca Raton, CRC Press, pp. 141-179, 1985.
2. Guminska M, Ignacak J, Kedryna T and Stachurska MB: Tumor-specific pyruvate kinase isoenzyme M2 involved in biochemical strategy of energy generation in neoplastic cells. Acta Biochim Pol 44: 711-724, 1997.
3. Hacker HJ, Steinberg P and Bannasch P: Pyruvate kinase isoenzyme shift from L-type to M2-type is a late event in hepatocarcinogenesis induced in rats by a choline-deficient/DL-ethionine-supplemented diet. Carcinogenesis 19: 99-107, 1998.
4. Reinacher M and Eigenbrodt E: Immunohistological demonstration of the same type of pyruvate kinase isoenzyme (M2-PK) in tumors of chicken and rat. Virchows Arch B Cell Pathol Incl Mol Pathol 37: 79-88, 1981.
5. Staal GEJ and Rijksen G: Pyruvate kinase in selected human tumors. In: Biochemical and Molecular Aspects of Selected Cancers. Pretlow TG and Pretlow TP (eds.). San Diego, Academic Press, pp. 313-337, 1993.
6. Presek P, Reinacher M and Eigenbrodt E: Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett 242: 194-198, 1988.
7. Ashizawa K, Willingham MC, Liang CM and Cheng SY: In vivo regulation of monomer-tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1,6-bisphosphate. J Biol Chem 266: 16842-16846, 1991.
8. Mazurek S, Zwerschke W, Jansen-Durr P and Eigenbrodt E: Effects of the human papilloma virus HPV-16 E7 oncoprotein on glycolysis and glutaminolysis: role of pyruvate kinase type M2 and the glycolytic-enzyme complex. Biochem J 356: 247-256, 2001.
9. Mazurek S, Boschek CB, Hugo F and Eigenbrodt E: Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol 15: 300-308, 2005.
10. Hentze MW: Enzymes as RNA-binding proteins: a role for (di)nucleotide-binding domains? Trends Biochem Sci 19: 101-103, 1994.
11. Nagy E and Rigby WF: Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold). J Biol Chem 270: 2755-2763, 1995.
12. Mazurek S, Eigenbrodt E, Failing K and Steinberg P: Alterations in the glycolytic and glutaminolytic pathways after malignant transformation of rat liver oval cells. J Cell Physiol 181: 136-146, 1999.
13. Mazurek S, Grimm H, Wilker S, Leib S and Eigenbrodt E: Metabolic characteristics of different malignant cancer cell lines. Anticancer Res 18: 3275-3282, 1998.
14. Miccheli A, Tomassini A, Puccetti C, Valerio M, Peluso G, Tuccillo F, Calvani M, Manetti C and Conti F: Metabolic profiling by 13C-NMR spectroscopy: [1,2-13C2] glucose reveals a heterogeneous metabolism in leukemia T cells. Biochimie 88: 437-448, 2006.
15. Perez-Gomez C, Campos-Sandoval JA, Alonso FJ, Segura JA, Manzanares E, Ruiz-Sanchez P, Gonzalez ME, Marquez J and Mates JM: Co-expression of glutaminase K and L isoenzymes in human tumour cells. Biochem J 386: 535-542, 2005.
16. Goossens V, Grooten J and Fiers W: The oxidative metabolism of glutamine. A modulator of reactive oxygen intermediate-mediated cytotoxicity of tumor necrosis factor in L929 fibrosarcoma cells. J Biol Chem 271: 192-196, 1996.
17. Gomez-Fabre PM, Aledo JC, Del Castillo-Olivares A, Alonso FJ, Nunez De Castro I, Campos JA and Marquez J: Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem J 345: 365-375, 2000.
18. Lobo C, Ruiz-Bellido MA, Aledo JC, Marquez J, Nunez De Castro I and Alonso FJ: Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J 348: 257-261, 2000.
19. Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ and Capaldi RA: Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 64: 985-9931, 2004.
20. Le Mellay V, Houben R, Troppmair J, Hagemann C, Mazurek S, Frey U, Beigel J, Weber CM, Benz R, Eigenbrodt E and Rapp U: Regulation of glycolysis by Raf protein serine/ threonine kinases. Adv Enzyme Regul 42: 317-332, 2002.
21. Huleihel M, Goldsborough M, Cleveland J, Gunnell M, Bonner T and Rapp UR: Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol 6: 2655-2662, 1986.
22. Mercer K, Chiloeches A, Huser M, Kiernan M, Marais R and Pritchard C: ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf. Oncogene 21: 347-355, 2002.
23. Pritchard CA, Bolin L, Slattery R, Murray R and McMahon M: Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. Curr Biol 6: 614-617, 1996.
24. Mazurek S and Eigenbrodt E: The tumor metabolome. Anticancer Res 23: 1149-1154, 2003.
25. Spittler A, Oehler R, Goetzinger P, Holzer S, Reissner CM, Leutmezer F, Rath V, Wrba F, Fuegger R, Boltz-Nitulescu G and Roth E: Low glutamine concentrations induce phenotypical and functional differentiation of U937 myelomonocytic cells. J Nutr 127: 2151-2157, 1997.
26. Zebisch A and Troppmair J: Back to the roots: the remarkable RAF oncogene story. Cell Mol Life Sci 63: 1314-1330, 2006.
27. Giugni TD, Chen K and Cohen S: Activation of a cytosolic serine protein kinase by epidermal growth factor. J Biol Chem 263: 18988-18995, 1988.
28. Weernink PA, Rijksen G, Mascini EM and Staal GE: Phosphorylation of pyruvate kinase type K is restricted to the dimeric form. Biochim Biophys Acta 1121: 61-68, 1992.
29. Weernink PA, Rijksen G, van der Heijden MC and Staal GE: Phosphorylation of pyruvate kinase type K in human gliomas by a cyclic adenosine 5′-monophosphate-independent protein kinase. Cancer Res 50: 4604-4610, 1990.
30. Siwko S and Mochly-Rosen D: Use of a novel method to find substrates of protein kinase C delta identifies M2 pyruvate kinase. Int J Biochem Cell Biol 39: 978-987, 2007.
31. Kuznetsov AV, Janakiraman M, Margreiter R and Troppmair J: Regulating cell survival by controlling cellular energy production: novel functions for ancient signaling pathways? FEBS Lett 577: 1-4, 2004.
32. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davies N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais S, Marshall CJ, Wooster R, Stratton MR and Futreal PA: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
33. Zebisch A, Staber PB, Delavar A, Bodner C, Hiden K, Fischereder K, Janakiraman M, Linkesch W, Auner HW, Emberger W, Windpassinger C, Schimek MG, Hoefler G, Troppmair J and Sill H: Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia. Cancer Res 66: 3401-3408, 2006.
34. Konopleva M, Shi Y, Steelman LS, Shelton JG, Munsell M, Marini F, McQueen T, Contractor R, McCubrey JA and Andreeff M: Development of a conditional in vivo model to evaluate the efficacy of small molecule inhibitors for the treatment of Raf-transformed hematopoietic cells. Cancer Res 65: 9962-9970, 2005.
35. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D and Marais R: Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867, 2004.
36. Weber CK, Slupsky JR, Kalmes HA and Rapp UR: Active Ras induces heterodimerization of c-Raf and B-Raf. Cancer Res 61: 3595-3598, 2001.
37. Mercer K, Giblett S, Oakden A, Brown J, Marais R and Pritchard C: A-Raf and Raf-1 work together to influence transient ERK phosphorylation and G1/S cell cycle progression. Oncogene 24: 5207-5217, 2005.
38. Schreck R and Rapp UR: Raf kinases: oncogenesis and drug discovery. Int J Cancer 119: 2261-2271, 2006.
39. Zebisch A, Czernilofsky AP, Keri G, Smigelskaite J, Sill H, Troppmair J: Signaling through RAS-RAF-MEK-ERK: from basics to bedside. Curr Med Chem 14: 601-623, 2007.
40. Dombrauckas JD, Santarsiero BD and Mesecar AD: Structural basis of tumor M2 allosteric regulation and catalysis. Biochemistry 44: 9417-9429, 2005.